Multifunctional poly (lactide-co-glycolide) nanoparticles for luminescence/magnetic resonance imaging and photodynamic therapy

Lee, Dong Jin; Park, Ga Young; Oh, Kyung Taek; Oh, Nam Muk; Kwag, Dong Sup; Youn, Yu Seok; Oh, Young-Jin; park, Jin woo; Lee, Eun Seong

doi:10.1016/j.ijpharm.2012.05.068

Cited by 37 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7b. These results are in accordance with the results obtained by Lee et al (2012) and Fadel et al (2010). They formulated nanoparticles from the biodegradable copolymer poly (lactic-co glycolic acid) (PLGA) for targeting of zinc (II) phthalocyanine (ZnPc) for PDT in Ehrlich ascites carcinoma bearing mice.…”

Section: Tumor Growth and Growth Ratesupporting

confidence: 90%

Enhanced photodynamic efficacy of PLGA-encapsulated 5-ALA nanoparticles in mice bearing Ehrlich ascites carcinoma

et al. 2013

View full text Add to dashboard Cite

Nanoparticles (NPs) fabricated from the biodegradable copolymer poly(lactic-co-glycolic acid) (PLGA) were investigated as a drug delivery system to enhance the photodynamic efficacy of 5-aminolevulinic acid (5-ALA) in mice bearing Ehrlich ascites carcinoma. The PLGA-encapsulated 5-ALA NPs were prepared using binary organic solvent diffusion method and characterized in terms of shape and particle size. The in vivo photodynamic efficiency in Ehrlich ascites-bearing mice was studied. The obtained particles were uniform in size with spherical shape of mean size of 249.5 nm as obtained by particle size analyzer and the in vitro release studies demonstrated a controlled release profile of 5-ALA. Tumor-bearing mice injected with PLGA-encapsulated 5-ALA NPs exhibited significantly smaller mean tumor volume, increased tumor growth delay compared with the control group and the group injected with free 5-ALA during the time course of the experiment. Histopathological examination of tumor from mice treated with PLGAencapsulated 5-ALA NPs showed regression of tumor cells, in contrast to those obtained from mice treated with free 5-ALA. The results indicate that PLGA-encapsulated 5-ALA NPs are a successful delivery system for improving photodynamic activity in the target tissue.

show abstract

Section: Tumor Growth and Growth Ratesupporting

confidence: 90%

Enhanced photodynamic efficacy of PLGA-encapsulated 5-ALA nanoparticles in mice bearing Ehrlich ascites carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…However, when Ce6 was conjugated to PEG-PLL-PLA, its solubility was maintained regardless of pH condition. 35,36 Figure 3A shows the change in FI of CDTM and free Ce6. When the pH decreased from 7.4 to 4.5, the intensity of free Ce6 decreased due to aggregation, whereas CDTM showed a consistent FI over the whole pH range, demonstrating the conjugation of Ce6 to the lysine residue.…”

Section: Characterization Of Ph-sensitive Cdtmmentioning

confidence: 99%

“…Although the free Ce6 showed the highest phototoxicity in in vitro conditions, there were no significant differences in tumor volume changes between the PBS and free Ce6 groups in vivo due to lack of tumor targeting ability of free Ce6. 36,45,46 No dramatic weight change was observed in the mice treated with any sample, indicating no apparent systemic toxicity ( Figure 6B). The optical images of tumor-bearing mice at days 0 and 15 were presented in Figure 6C to visualize the tumor growth inhibition.…”

mentioning

confidence: 94%

A charge-reversible nanocarrier using PEG-PLL(-<em>g</em>-Ce6, DMA)-PLA for photodynamic therapy

Lim

Sim

Hoang

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

A polyelectrolyte nanoparticle composed of PEG-PLL(- g -Ce6, DMA)-PLA was developed for nanomedicinal application in photodynamic therapy. These nanoparticles formed stable aggregates through the hydrophobic interaction of poly(lactic acid) and demonstrated pH-dependent behaviors such as surface charge conversion and enhanced cellular uptake at acidic pH, resulting in improved phototoxicity. In vivo animal imaging revealed that the prepared PEG-PLL(- g -Ce6, DMA)-PLA nanoparticles effectively accumulated at the targeted tumor site through enhanced permeability and retention effects. Reversible surface charge for PEG-PLL (- g -Ce6, DMA)-PLA nanoparticles allows the nanoparticles to escape the immune system and concentrate on the tumor tissue. Tumor growth in the nude mice treated with the nanoparticles decreased significantly and the hydrophobic interaction in the poly(lactic acid) block could allow the incorporation of multiple drugs. Therefore, the PEG-PLL(- g -Ce6, DMA)-PLA nanoparticles could have considerable potential as a nanomedicinal platform for photodynamic therapy.

show abstract

“…And the appropriate outer surface engineering (such as PEGylation) of PLGA-based DDSs may prolong the blood circulation time of the DDSs (Graf et al, 2012). Chemotherapeutic drugs, photosensitizers, photothermal agents, therapeutic gene/siRNA, small-molecule inhibitors, and other therapeutic agents can be easily loaded in the PLGA-based DDSs for tumor treatment (Lee et al, 2012;Zhao et al, 2015;Shen et al, 2017Shen et al, , 2019. Furthermore, the imaging agents can also be integrated into PLGA-based DDSs to acquire the imaging property for tumor diagnosis (Chen et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications

Shen

Xie

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Intelligent drug delivery systems based on nanotechnology have been widely developed and investigated in the field of nanomedicine since they were able to maximize the therapeutic efficacy and minimize the undesirable adverse effects. Among a variety of organic or inorganic nanomaterials available to fabricate drug delivery systems (DDSs) for cancer therapy and diagnosis, poly(D,L-lactic-co-glycolic acid) (PLGA) has been extensively employed due to its biocompatibility and biodegradability. In this paper, we review the recent status of research on the application of PLGAbased drug delivery systems (DDSs) in remotely triggered cancer therapy and the strategies for tumor imaging provided by PLGA-based DDSs. We firstly discuss the employment of PLGA-based DDSs for remotely triggered cancer therapy, including photo-triggered, ultrasound-triggered, magnetic field-triggered, and radiofrequencytriggered cancer therapy. Photo-triggered cancer therapy involves photodynamic therapy (PDT), photothermal therapy (PTT), and photo-triggered chemotherapeutics release. Ultrasound-triggered cancer therapy involves high intensity focused ultrasound (HIFU) treatment, ultrasound-triggered chemotherapeutics release, and ultrasoundenhanced efficiency of gene transfection. The strategies which endows PLGA-based DDSs with imaging properties and the PLGA-based cancer theranostics are further discussed. Additionally, we also discuss the targeting strategies which provide PLGAbased DDSs with passive, active or magnetic tumor-targeting abilities. Numerous studies cited in our review demonstrate the great potential of PLGA-based DDSs as effective theranostic agent for cancer therapy and diagnosis.

show abstract

Multifunctional poly (lactide-co-glycolide) nanoparticles for luminescence/magnetic resonance imaging and photodynamic therapy

Cited by 37 publications

References 32 publications

Enhanced photodynamic efficacy of PLGA-encapsulated 5-ALA nanoparticles in mice bearing Ehrlich ascites carcinoma

Enhanced photodynamic efficacy of PLGA-encapsulated 5-ALA nanoparticles in mice bearing Ehrlich ascites carcinoma

A charge-reversible nanocarrier using PEG-PLL(-<em>g</em>-Ce6, DMA)-PLA for photodynamic therapy

PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications

Contact Info

Product

Resources

About